IO Biotech, Inc. (IOBTQ) Accumulated Expenses (2020 - 2025)

IO Biotech (IOBTQ) has 6 years of Accumulated Expenses data on file, last reported at $11.9 million in Q3 2025.

• Quarterly Accumulated Expenses rose 18.12% year-over-year to $11.9 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $11.9 million (up 18.12% YoY) and the FY2024 annual result came in at $14.1 million, up 26.14% from the prior year.
• Accumulated Expenses fell to $11.9 million in Q3 2025, from $13.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $14.1 million in Q4 2024 to a low of $538000.0 in Q3 2021.
• A 5-year average of $7.0 million and a median of $6.2 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2021 — Accumulated Expenses soared 712.36% — and 2023, when it sank 68.48%.
• Tracing IOBTQ's Accumulated Expenses over 5 years: stood at $6.4 million in 2021, then slipped by 3.45% to $6.2 million in 2022, then soared by 81.65% to $11.2 million in 2023, then climbed by 26.14% to $14.1 million in 2024, then fell by 15.4% to $11.9 million in 2025.
• The last three Accumulated Expenses figures came in at $11.9 million (Q3 2025), $13.6 million (Q2 2025), and $12.4 million (Q1 2025), per Business Quant data.